0000049071-26-000009
SEC filingHumana's 2025 revenue grew 10.1% to $129.7B, but net income slightly declined to $1.2B as benefit ratio rose 40bps to 90.2% and operating cost ratio increased 20bps.
Humana Inc. describes itself as a company committed to 'putting health first' through its Humana insurance services and CenterWell health care services. Headquartered in Louisville, Kentucky, the Company serves approximately 15 million members in medical benefit plans and 4.7 million members in specialty products as of December 31, 2025. A critical fact disclosed in this section is that 83% of total premiums and services revenue in 2025 came from contracts with the federal government, with 14% derived from individual Medicare Advantage contracts in Florida alone.
Humana operates two reportable segments. The Insurance segment generated 96.3% of consolidated premiums and services revenue in 2025, and includes Medicare products (individual and group Medicare Advantage, stand-alone PDP, and Medicare Supplement), state-based contracts (Medicaid and MLTSS), specialty benefits (dental, vision, life, disability), the Pharmacy Benefit Manager (PBM) business, and military services (TRICARE). The CenterWell segment generated 3.7% of consolidated external services revenue and includes pharmacy solutions (CenterWell Pharmacy, CenterWell Specialty Pharmacy), primary care (operating under Conviva Senior Primary Care and CenterWell Senior Primary Care brands), and home solutions (CenterWell Home Health, OneHome, and a minority interest in Gentiva Hospice).
Key products include Individual Medicare Advantage plans offered under HMO, PPO, PFFS, and D-SNP structures; Group Medicare Advantage; stand-alone prescription drug plans (including a co-branded Humana-Walmart PDP); Medicare Supplement; state-based contracts serving Medicaid and dual-eligible members; specialty benefits (dental, vision, life, disability); and military services under the TRICARE T-5 East Region contract (covering 24 states and Washington D.C., approximately 4.6 million beneficiaries). CenterWell operates 350 primary care clinics with approximately 1,300 primary care providers serving 491,100 patients, primarily under risk-sharing arrangements.
Humana markets its products through approximately 1,000 sales representatives and 2,200 telemarketing representatives, as well as licensed independent brokers, agents, and wholesale distributors. The Company has a marketing arrangement with Walmart Inc. for its individual Medicare stand-alone PDP plan. Group Medicare Advantage products are sold through large employers. Highly concentrated customers include the federal government (83% of revenue), with specific dependency on CMS contracts in Florida ($17.8 billion in 2025, or 20% of individual Medicare Advantage premiums). All material contracts with CMS for Medicare Advantage and PDP products have been renewed for 2026.
The health benefits industry is described as 'highly competitive.' Competitors vary by local market and include other managed care companies, national insurance companies, and other HMOs and PPOs. The filing notes that many competitors have a larger membership base and/or greater financial resources in the markets where Humana competes.
At the core of Humana's strategy is its 'integrated care delivery model,' which unites quality care, high member engagement, and sophisticated data analytics. Three core elements are improving the consumer experience, engaging members in clinical programs, and assisting providers in transitioning from fee-for-service to value-based arrangements. As of December 31, 2025, 15.1% of medical membership (including 37.1% of individual Medicare Advantage members) was covered under shared risk value-based arrangements. The Company also emphasizes primary, physician-directed care designed to improve health outcomes and affordability, and it operates 146 primary care clinics through a strategic partnership with Welsh, Carson, Anderson & Stowe (WCAS).
As of December 31, 2025, Humana employed approximately 67,060 associates. The Company reports an average tenure of 7 years and a voluntary turnover rate of 13.8% in 2025 (down from 14.4% in 2024). The Company conducts an annual confidential, third-party administered Engagement Survey and uses continuous listening campaigns. Total Rewards include competitive base pay, 401(k) matching, medical/dental/vision benefits, paid parental leave (6 weeks), paid caregiver time off (2 weeks), tuition assistance, and well-being programs. The Company also conducts an annual pay equity/gap analysis.
Humana's consolidated revenue for 2025 increased 10.1% to $129.7 billion, driven by a 9.6% rise in Insurance premiums to $122.8 billion and a 31.6% increase in services revenue to $5.8 billion. Premium growth was led by higher per-member Medicare premiums (boosted by IRA direct subsidies) and membership expansion in state-based contracts and stand-alone PDP, partially offset by a 7.3% decline in individual Medicare Advantage membership due to plan exits. Services revenue growth came from CenterWell's primary care and pharmacy solutions.
The benefit ratio increased 40 basis points to 90.2% as favorable prior-period claims development (1.0B vs. 701M) was more than offset by a shift toward higher-ratio lines (state-based, PDP), investments in member outcomes, and the IRA's impact on PDP. The operating cost ratio rose 20 basis points to 12.0% due to business mix shifts toward CenterWell (which has a higher ratio), operating leverage loss from Medicare Advantage membership decline, and higher value creation charges, partly offset by administrative efficiencies.
Operating income grew 5.5% to $2.70 billion. However, net income fell 0.9% to $1.20 billion ($9.84 EPS) as higher other expenses (including $513M put/call valuation adjustments and $253M impairment charges) and a $67M loss on sale of business weighed on results. The effective tax rate dropped to 17.4% from 25.5% due to a tax benefit from the loss on sale.
Insurance Segment: Operating income surged 29.1% to $1.66 billion, with the benefit ratio flat at 90.4% and the operating cost ratio improving 10bps to 9.1%. The stable benefit ratio reflected pricing actions and favorable prior-year development offsetting mix headwinds and IRA effects. Cost efficiencies from value creation initiatives helped lower the operating cost ratio despite membership volume declines.
CenterWell Segment: Revenues grew 39% to $4.82 billion externally (and 12.7% total including intersegment), driven by primary care and pharmacy solutions growth, partially offset by the v28 risk model revision. However, operating income was nearly flat at $1.34 billion as the operating cost ratio increased 90bps to 93.1% due to the v28 phase-in and higher-mix specialty pharmacy. Overall, CenterWell remains a high-cost, high-growth segment.
Management provided 2026 membership growth guidance: individual Medicare Advantage ~25%, group Medicare Advantage ~150,000 members, stand-alone PDP ~1,000,000 members, and state-based contracts 25,000–100,000 members. This signals confidence in returning to growth after the 2025 exit from unprofitable plans. Additionally, on February 13, 2026, Humana completed the acquisition of a primary care business for ~$941 million, reinforcing its integrated care delivery strategy. The company expects continued benefits from value creation initiatives to drive administrative efficiencies, though the IRA's impact on PDP will persist. No specific financial guidance for 2026 was provided in the MD&A.
As of December 31, 2025, Humana held $4.2 billion in cash and cash equivalents, up from $2.221 billion at year-end 2024. Total investment securities (current and long-term) were $16.196 billion in fair value, a decrease from $18.635 billion in 2024. Total debt increased to $12.369 billion from $11.144 billion, driven by $1.481 billion in new senior notes issuance, partially offset by $948 million in repayments and $256 million in net repurchases of senior notes. Stockholders' equity rose to $17.657 billion from $16.375 billion, supported by net income and other comprehensive income.
Purchase obligations total $1.2 billion in 2026, $953 million in 2027, $595 million in 2028, $298 million in 2029, and $273 million in 2030. These primarily relate to information technology services and real estate improvements. Additionally, Humana has entered into a strategic partnership with WCAS involving put and call options for primary care clinics, with potential purchase prices ranging from $1.0 billion to $1.5 billion for the first two cohorts in 2026, and $3.0 billion to $5.0 billion for all existing cohorts from 2026 to 2034. The fair value of the put option liability is $1.4 billion and the call option asset is $13 million as of December 31, 2025.
During 2025, Humana repurchased 0.4 million shares for $100 million in open market transactions. The remaining repurchase authorization was $2.7 billion as of February 18, 2026. Dividends totaled $426 million for the year, with a quarterly dividend of $0.885 per share. Capital expenditures were $546 million, representing 0.4% of total revenues. The company issued $1.481 billion in senior notes and repaid $256 million net of notes repurchased. Ordinary dividends from regulated subsidiaries to the parent company are expected to be approximately $1.1 billion in 2026.
No segment-level financial data is disclosed in the Notes to Financial Statements. The only segment breakdown provided relates to goodwill: $2.663 billion in Insurance and $7.023 billion in CenterWell. Revenue concentration is noted in the Reporting Entity footnote: approximately 83% of total premiums and services revenue came from contracts with the federal government in 2025, including 14% related to CMS contracts for Medicare Advantage members in Florida.
Net income of $1,203M in 2025 was only slightly below the prior year's $1,214M, yet operating cash flow collapsed from $2,966M to $921M. This divergence highlights significant working capital outflows: receivables increased by $570M, other assets consumed $2,173M, and benefits payable decreased by $472M. These swings overwhelmed the positive contributions from non-cash charges (depreciation $773M, stock-based compensation $241M, impairments $156M).
Capital expenditure intensity remained high at $546M, representing 59% of operating cash flow, leaving limited free cash flow for capital returns. Share repurchases were slashed to $151M from $817M in 2024, and dividends held steady at $430M. The investing section showed a net inflow of $2,273M, driven by large sales of investment securities ($6,510M) partially offset by purchases ($6,440M). Financing activities used $1,215M, including $1,481M in new senior note issuance offset by $948M in repayments.
Overall, cash flow quality deteriorated markedly in 2025 due to working capital drag, despite stable net income. The company relied on investment portfolio turnover to generate investing cash inflows, while financing activities reflected a net reduction in debt and equity returns.